Compare DexCom, Inc. (DXCM) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Workiva Inc — how do they compare? DexCom, Inc. trades at $84.47 (market cap $31.86B), while Workiva Inc trades at $73.68 (market cap $4.01B). The key difference: DexCom, Inc. is far larger — about 7.9× Workiva Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Workiva Inc for 21 Days on average.
| DXCM | WK | |
|---|---|---|
Market Cap | $31.86B | $4.01B |
Volume | 3,607,070 | 1,301,708 |
Sector | Health | Technology |
52-Week High | $92.34 | $93.31 |
52-Week Low | $54.84 | $44.31 |
Typical Hold Time | 62 Days | 21 Days |
Enterprise Value | $31.32B | $3.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
WK trades at $73.79, up 3.16% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $0.798. Revenue grew to $966 million in 2026, turning a net loss in 2025 into a $47 million profit. Analyst sentiment is overwhelmingly positive, with 16 buy ratings and a consensus price target of $86.
The outlook for WK is favorable, driven by consistent earnings outperformance and revenue growth, though high valuation multiples like a P/E of 87.73 pose risks. Key opportunities include AI-driven product innovations and inclusion in investment analyses, while risks involve competitive pressures and reliance on continued execution. The stock's proximity to its 52-week high suggests momentum but warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
